21st Century Innovative Technologies and Developments as also discoveries, curiosity ( insolite)...

Quick COVID breathalyzer could allow mass screening in public places
(Nanowerk News) According to experts, bringing an end to the pandemic will require rapid screening of people attending large gatherings, such as conferences and weddings. Even those who are asymptomatic can still transmit COVID-19 to others, making it important to identify and isolate them until they are no longer contagious.
Now, researchers reporting in ACS Nano ("Noninvasive and Point-of-Care Surface-Enhanced Raman Scattering (SERS)-Based Breathalyzer for Mass Screening of Coronavirus Disease 2019 (COVID-19) under 5 min") have developed a prototype “breathalyzer” that can sensitively and accurately diagnose COVID-19, even in asymptomatic individuals, in less than 5 minutes.

Learn more / En savoir plus / Mehr erfahren:

http://www.scoop.it/t/21st-century-innovative-technologies-and-developments/?tag=Nano

https://www.scoop.it/topic/21st-century-innovative-technologies-and-developments/?&tag=COVID19

Victorian hologram keeps music in touch with lockdown audience

LONDON (Reuters) - Musicians are using an interactive hologram based on Victorian technology to reach fans in the locked down world of the coronavirus pandemic.

Learn more / En savoir plus / Mehr erfahren: 

https://www.scoop.it/topic/21st-century-innovative-technologies-and-developments/?&tag=Coronavirus

New York (CNN Business)Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion (ALXN) for $39 billion.

The acquisition is one of the largest deals of the year for the drug industry and would expand AstraZeneca's (AZN) reach in rare diseases. Alexion has an immunology unit in Boston that serves patients with rare disorders.
AstraZeneca, a British-Swedish drugmaker headquartered in the United Kingdom, has partnered with the University of Oxford to produce a Covid-19 vaccine. It's in the final stages of development and is awaiting authorization from European and British governments. Last month, the company found its vaccine was 70% effective on average, but scientific experts raised concerns over a lack of transparency in reporting the vaccine trial data, potentially slowing down the timeline for approval.
AstraZeneca agreed to pay for the purchase with a mix of cash and stock, and said it took out a short-term loan of $17.5 billion from Morgan Stanley, J.P. Morgan and Goldman Sachs to help pay for it.

Learn more / En savoir plus / Mehr erfahren: 

https://www.scoop.it/topic/21st-century-innovative-technologies-and-developments/?&tag=Research

https://www.scoop.it/topic/21st-century-innovative-technologies-and-developments/?&tag=Coronavirus

https://www.scoop.it/topic/21st-century-innovative-technologies-and-developments/?&tag=Acquisitions